Phase Ia study to assess the safety and pharmacology of PAS-393 in human volunteers
Latest Information Update: 18 Sep 2020
At a glance
- Drugs PAS-393 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 18 Sep 2020 New trial record
- 15 Sep 2020 According to a Pascal Biosciences media release, Pascal Biosciences and SoRSE technology have entered into a Collaborative Research Agreement to advance Pascals PAS-393 into clinical testing in human volunteers. Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SoRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor.